Eran Elinav | |
|---|---|
| ערן אלינב | |
 Eran Elinav | |
| Born | June 22, 1969 |
| Citizenship | Israeli |
| Alma mater | Hebrew University in Jerusalem, Hadassah-Hebrew University Medical Center, Weizmann Institute of Science |
| Organization(s) | Weizmann Institute of Science, German Cancer Research Center |
| Spouse | Hila |
| Children | Shira, Omri, Inbal |
| Awards | Rappaport prize for biomedical research, Levinson award for basic science research, Landau prize of Immunology |
| Website | www |
Eran Elinav (born 22 June 1969 in Jerusalem, Israel) is an Israeli immunologist[1] and microbiota researcher[2] at the Weizmann Institute of Science[3] and the DKFZ.[4]
He is an international scholar at the Howard Hughes Medical Institute (HHMI) and the Bill & Melinda Gates Foundation[5] and a senior fellow of the Canadian Institute for Advance Research (CIFAR).[6]
Elinav earned a M.D. from the Hebrew University in Jerusalem in 1999. Following an internship and residency in internal medicine at the Hadassah-Hebrew University Medical Center in 2000–2004.
He served as a senior physician-scientist at the Tel Aviv Sourasky Medical Center Institute of Gastroenterology and Liver Disease in 2005–2009.[2]
In 2009 Elinav earned a Ph.D. in immunology from the Weizmann Institute of Science, advised by Zelig Eshhar, after developing the Chimeric Antigen Receptor Regulatory T cell (CAR-Treg) approach,[7] as treatment of inflammatory bowel disease and autoimmunity. In 2009-2012 he followed by a post-doc at Yale University, advised by Richard Anthony Flavell, in which he discovered the NLRP6 inflammasome.[8]
In 2012 Elinav moved to the Weizmann Institute of Science and in 2016 was made a professor.[3] He heads the Institute of Microbiome research[9] and the Center of Host-Pathogen Interaction Research at the Weizmann Institute of Science and the Microbiome & Cancer Division at the DKFZ.[4] Since 2022, he heads the Department of Systems Immunology, Weizmann Institute of Science.
Elinav studies the molecular basis of host-microbiota interactions,[10] and their effects of diet,[11][12] environmental factors,[13] immune function[14] and host genetics[15] on the intestinal microbiome and associated multi-factorial metabolic,[16][17] inflammatory,[18] malignant[19] and neurogenerative disease.[20][21] His most-cited papers have more than 2,000 cites each.[22]
Elinav developed precision microbiota interventions, including Personalized Nutrition,[23][24] Precision Probiotics,[25] small molecule ″postbiotics″,[12] Phage Therapy,[26] [27] autologous fecal microbiome transplantation,[28][29] Vaginal Microbiome Transplantation (VMT) [30][31] and gut epithelial[32][33] interventions.
In 2014 Elinav discovered that people consuming identical foods and additives, such as non-nutritive sweeteners,[23][34] general foods[24] and bread,[35][36] feature a unique and personalized glycemic response, thereby potentially explaining the lack of uniform metabolic responses to generalized dietary approaches. [37]Personalized dietary recommendations,[38] based on individualized dietary, [39]clinical and microbiota data, improved pre-diabetes control.[24] He similarly showed, that consumption of probiotics[40] leads to a person-specific colonization resistance and physiological patterns.[41]
Elinav discovered, that the gut microbiota features a compositional and functional diurnal activity during a 24-hour cycle, which is dictated by host and environmental factors, mainly by the timing in food consumption. [42][43] These microbiota diurnal activities are tightly coordinated with the host gastrointestinal and systemic circadian activity,[44] while disruption of circadian activity by jet-lag[45] or shift work may lead to alterations in the microbiota behavior, which contribute to the development of common metabolic,[43] immune[18] and liver diseases.[46][44]
Elinav was awarded the Rappaport prize for biomedical research in 2015,[47] the Levinson award for basic science research in 2016,[48] the Landau prize of Immunology in 2018[49] and was inducted to the American Academy of Microbiology in 2021.[50]
